Anti-Depression a Systematic Review of Analytical methods in Pharmaceuticals

DURGADEVI Perumal[1], MANIKANDAN krishnan[1], and LAKSHMI K.S[1]

[1]Affiliation not available

June 30, 2022

Abstract

Major depressive disorder (MDD) is one of the most prevalent mental diseases. The first monoamine-based antidepressants were designed for treating MDD. Ketamine and its analogues were recently launched as fast-acting antidepressants. Unfortunately, the present therapeutic alternatives are insufficient; their lack of effectiveness, hazards and unwanted effects and patients with few therapy options. Efforts are currently being directed at understanding the genesis of depression and discovering new pharmaceutical therapy. In this review, we examine possible new pharmaceutical targets for the treatment of major depressive illness. Antidepressant effects may be obtained by targeting receptors such as peroxisome proliferator-activated receptors, G-protein-coupled receptors, opioid receptors and galanin receptors. This study highlights the anti-inflammatory activity of SNRIs & SSRIs anti-depression therapy, as well as the specific issues for each medication. In addition, we present outline of the depression theory and underlying processes. Furthermore, natural goods such as herbs, plants and fatty acids alleviated depression behaviours and symptoms. This review will present a brief history of medically accessible antidepressants, with a special focus on innovative pharmacological methods that have shown potential antidepressant activity in clinical and preclinical research. As a conclude SSRIs and SNRIs have an Anti-inflammatory role which might contribute the Anti-depressant activity.

1. Introduction

One of the world's most frequent mental health problems is major depressives disorders (MDD). MDD is a heterogeneous condition in which people experience distinct combinations of symptoms and respond differently, necessitating tailored treatment.[1] The monoamine deficiency theory, which states that monoamines neurotransmitters insufficiency is the major causes of MDD, fuelled the creation of the first antidepressants medicines in the 1960s. As a result, the first generations of antidepressants monoamine oxidases inhibitors (MAOIs) and later tricyclics antidepressant drugs (TCAs) were developed. Eventually, the involvement of serotonins in MDD, which led to the creation of currents first-lines therapies.

The use of anti-inflammatory medicines in antidepressant therapy regimens lends credence to the hypothesised relationship between inflammation and subgroups of people suffering from serious depression.[2]

In preclinical studies, the anti-depressant mechanisms of repetitive transcranial magnetic stimulation included anti-inflammatory effects mediated by activation of the nuclear factor-E2-related factor 2 signalling pathway via inhibition of the NMDA receptor.[3] Because of their potential ease anxiety or depression, exhibited anti-inflammatory and anti-depressive actions.[4]

MDD is a prevalent mental condition that has a multiple aetiology and a complicated pathophysiology. Treatment resistant depression (TRD) remains a serious issue, especially for individuals with severes depressive symptoms, including suicidal thoughts, who require effective and fast management. Because of its relation to MDD and therapeutic response, inflammation has attracted a lot of research. Ketamine, a dissociative anaesthetics, has a distinctive rapid-actings antidepressants effects at lower doses. Ketamine's anti-inflammatory properties play an important part in the processes underlying its antidepressant benefits.[5]

In order to comprehend the mechanisms behind ketamine's therapeutic activity, the development of effective drugs that work quickly and have a dual impact on both inflammation and MDD would be critical for the successful and individualised treatments of inflammatory-induced TRD, behaviour and suicidal thoughts. The combination of serum metabolomics and network pharmacology revealed the synergistic anti-depressive effects of distinct Xiaoyaosan efficacy groups[6]. Current medicine for anxiety disorders is inefficient and tolerable, emphasising the need for new pharmacological therapies.[7]

In this review, we combined the most recent studies on biological processes and receptors as well as numerous newer therapy alternatives with antidepressant properties, such as desvenlafaxine, vortioxetine, vilazodone, and levomilnacipran, that might serve as crucial potential targets to enhance MDD treatment results. Exploring fresh targets, finding alternative mechanisms of action for present antidepressants, or investigating synergistic substances for therapy are all ways to improve treatment options for patients.

Furthermore, we gave a detailed narrative overview of SSRIs and SNRIs, including escitalopram, fluoxetine, paroxetine, and venlafaxine, as well as their anti-inflammatory activity and implications in the MDD treatment. We examined the effects of SNRIs and SSRIs as reported in human or rodent depression models. As a result, the goal of this study is to offer a quick summary of currently available antidepressants as well as a comprehensive assessment of new moleculars targets with great prospects for the therapy of MDD. In doing so, we propose fresh methodologies for individualised antidepressant development that should be investigated further.

2. Material and Techniques

Systematic literatures reviews done the Medline and Scopus databases from 2014 until March 2022, and only publications authored and published in English were included. The search phrases included "escitalopram," "paroxetine," "fluoxetine," "venlafaxine," "desvenlafaxine," "vilazodone," "vortioxetine," and "levomilnacipran," as well as "pharmacological agents," "targeting receptors," and "inflammation" and "depression." Only studies based on human or rodent depression models were considered and included in this evaluation. We only considered publications concerning unipolar depression in research involving human individuals. In addition, we evaluated the references of the selected publications for additional studies that may be included in our research.

3. Antidepressants with Medical Approval

In this sections, antidepressants are generally accessible to people are addressed chronologically from the time they were developed. Despite the fact that these antidepressants are useful in the MDD patient treatments, they have a number of drawbacks, including side effects, administration hazards, delayed initiation of antidepressant medication, and limited effectiveness. As a result, we will briefly discuss the potential off-label applications, the efficacy of these medicines and restrictions for the MDD treatment in this section. Only papers created and published in English were included in systematic literature evaluations conducted in the Medline and Scopus databases. Drug, fluoxetine, prozac, effexor, contain large amounts, compounding, vortioxetine, and levomilnacipran were among the search terms, along with chemotherapeutic drugs, addressing targets, inflammation, and depression. In research human depression models were examined. Only papers that dealt with unipolar depression in human subjects were evaluated. In addition, we looked through the citations of the selected papers to see if there were any more studies that might be used on our study.

3.1. Inhibitors of Monoamine Oxidase

MDD is a heterogeneous condition characterised by a period of 15 days wherein a person shows any combination of everyday depressed symptoms such as social functioning, reduced occupational, mood changes, poor habits and daily activities, lack of interest and energy in recreational activities, sleep difficulties and changes in weight.[8]The ketamines is an effective antidepressant resulted in the approval of an esketamine nasal sprays.[9] Recent research has focused on the uses of MAOIss off-label for the treatments of Parkinson's diseases.[10] These investigations found that selegiline and rasagiline increased synaptics plasticity in animal models by recovering long-term stimulatory effects.[11]

3.2. Tricyclic antidepressants (TCAs)

DXP has been shown to enhance sleepiness in patients with MDD[12] and insomnia[13], with evidence of therapeutic effectiveness, while side effects are still an issue.

3.3. SSRI

The major objective of current research is to find critical parameters required to reduce undesirable effects and delay the commencement of therapeutics activity. SSRI-induceds over expression of brain-derived neurotrophics factors (BDNF) and dopamines receptor D1[14], SSRI antidepressant efficacy may be influenced by phosphorylations of the mammalians targets of rapamycin (mTOR)[15]. The distinct molecular pathways underpinning SSRI action may be an essential factor in understanding the origin of unpleasant effects and the delayed beginning of effectiveness, perhaps leading to the creation of superior treatments.

3.4. SNRI

Desvenlafaxine inhibits reuptakes major neurotransmitters implicated depressions: norepinephrine and serotonin [16]. Despite the documented effectiveness in treating MDDs patients, first-lines therapies are ineffective in many people, leading to delayed efficacy and various sides effects. This transferred the treatment need to fast-acting medicines with fewer side effects and greater effectiveness for TRD.

3.5 Anti-inflammatory effects of SNRIs and SSRIs in the treatment s of depression s

SNRIs & SSRIs have most evidence for treating depression of any antidepressant. According to current worldwide standards, for the treatments of depressions, SNRIs and SSRIs are first-line treatments[17]. Cytokines can interact indirectly or directly with microglias to stimulate them and perpetuate the inflammatory process. Microglias are normally located dormant condition, causing them to release cytokines (TNF[?], IL-6, IL-1β). During stress, danger-associated molecular patterns are generated, which activates a specific proteins.

Escitaloprams is most effective SSRI, bindings solely to the SERT and thereby raising serotonins levels in the CNS[18]. The investigation of specific brain areas implicated in the pathogenic process of depression provides a clearer perspective on the anti-inflammatory properties of escitalopram in depression. Fluoxetine was the first serotonin reuptakes inhibitors to be authorised for depression therapy. Fluoxetine has the ability to reduce inflammation while also increasing anti-inflammatory defence in depressions, in addition to having an antidepressants impact[19,20,21].

The consequences of SNRIs and SSRIs in people and rodent depression models were investigated. As a consequence, the purpose of this research is to provide a short overview of obtainable antidepressants as well as a complete review of emerging molecular targets with promising therapeutic potential for MDD. We propose new approaches for developing personalised antidepressants as a result, which should be examined further.

Paroxetine may have anti-inflammatory effects that are unrelated to its therapeutics purposes[22]. Furthermore, paroxetine lowered IL-1β and IL-18 production in remission patients who received paroxetines medication compared to depressive individuals who did not get treatment. Research data on paroxetine's possible anti-inflammatory effect is limited in comparison to other chemicals in the SSRI family. Alcocer-Gómez et al.[23], discovered a drop in IL-18 and IL-1β levels in the serums of patients in remissions after an occurrence of MDD and medicated with venlafaxines compares to non-treated individuals as a parts of venlafaxine's anti-inflammatory effect. All of these findings add to the complicated mechanisms of venlafaxine in depression treatment, elevating it above the level of an SNRI. As a result, evidence from the literature suggests that individuals with increased baseline inflammatory markers have worse clinical outcomes (Table 1).

3.6. Ketamine

Ketamine is a phencyclidine derivative that was created as an anaesthetic in the 1960s. It is an N-methyl-D-aspartates receptor (NMDAR) antagonist that is non-competitive. NMDARs are ionotropics glutamatergics

receptors that are activated by glutamate and glycine bindings to their respective bindings sites and inhibiteds by magnesium ions bindings to the phencyclidine site. Ketamines contains two active enantiomers: S-ketamine, which both have antidepressant properties (also called as esketamine) and R-ketamine (also called as arketamine). Although arketamine's decreased affinity for NMDAR, preclinical models revealed increased long-term antidepressant effects[27,28].

Extensive research is being performed as investigate critical elements mechanisms actions, objective generating therapies for MDD therapy, fewer side effects. Regulation of the neuropeptide precursor VGF[29], stimulation of the serotonin1A receptor[30], the-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)[31] induction, activation of the BDNF pathway and the ventral CA3 hippocampal regions are some of the proposed mechanisms. γ-Aminobutyrics acids is a neurotransmitters types in CNS: metabotropics receptors (GABAARs) & ionotropic (GABABRs). Ketamine's antidepressant effect is dependent on GABAB receptors[32]

4. Potential Antidepressants Targeting Receptors

Targeting receptor families and individual receptors implicated in the pathophysiology of depression is one method of creating novel therapeutics for MDD. In this part, we will look at clinical and preclinical studies that target certain receptor classes for the depression treatment. The receptors families listed here have received little attention in the field of depression research, although they have been shown to be interesting new therapy approaches.

4.1. Opioid Receptors

Opioid receptors kappa, delta(DOR), mu found all across neural systems govern critical physiologicals activities like the reward process, stress response and mood. Enkephalin (ENK), endorphin, dynorphin, and nociceptin/orphanin FQ bind to opioid receptors, activating them and causing a variety of downstream actions. Modulating opioid receptors with particular or non-specific agonists and antagonists has antidepressant potential. BUP/samidorphan combination therapy was similarly effective and in depressed individuals with no symptoms of misuse dependence[33,34]. Similarly, numerous has been found to counteract inflammation-induced depressive-like behaviours as well as cognitive impairment by lowering hypothalamic-pituitary-adrenal (HPA) axis hyperactivity and enhancing BDNF expression[35]. More research is needed to discover whether nalmefene has therapeutic potential for individuals.

Fluoxetine could have anti-inflammatory properties unconnected to its therapeutic goals. Furthermore, as compared to depressed persons who did not get therapy, paroxetine reduced IL-1 and IL-18 production in remission patients who got paroxetine medication. In compared to other compounds in the SSRI family, research on paroxetine's probable anti-inflammatory impact is sparse. Identified a decrease in IL-18 and IL-1 levels in the serums following, incidence who were medicated venlafaxines than non-treated individuals. All of these studies contribute to the venlafaxine's intricate processes in depression therapy, bringing it above the level of an SNRI. There is also the possibility of developing medicines for the treatment of MDD that target specific opioid receptors. SNC80 and Rubiscolin-6[36]reduce depressive-like behaviours in depression rodent models, interacts with the opioid receptor family's nociceptin receptor (NOPr)[37]. Tianaeptine decreased depressive-like behaviours in mice, and inflammatory markers in the prefrontal cortex (PFC) and hippocampus[38] had a favourable influence on energy and metabolic processes.

Several studies have found that combining tianeptine with another medication improves its effectiveness. Mice given medications exhibited less depressive-like behaviour[39]. Recently found a link for corticotropin and the antidepressant effects -releasing hormone receptor in individuals suffering from serious depression[40].

4.2. Receptors for N-methyl-D-aspartate

Glutamate bindings activates NMDARs and causes cell depolarization. The NMDAR antagonist nitrous oxide (N_2O) exhibits antidepressant characteristics comparable to ketamine. N_2O restored synaptic plasticity by activating neuronal nitric oxide synthase. BDNF expression was increased and neuron firing rate was increased in the mouse medial PFC[41]. N2O enhanced Hamilton Depressions Ratings remissions rates and had

an immediate high treatments rates[42]. Memantine, another NMDAR antagonist, was originated to be useful in treating MDD patients over the age of 60 when combined with normal SSRI medication. Importantly, no serious adverse effects were found[43], indicating that memantine might be used in combination with an SSRI to treat ageing people with MDD. To assess the possible limits of this therapy, more research is needed to identify whether the effects are age-specific. Other NMDAR antagonists have shown potential behavioural benefits in animals. Lacitine and MK-801 reversed stress-induced depressive-like behaviours quickly[44,45].

AGN-241751, an NMDAR positive allosteric modulator, significantly improved antidepressant behaviour by boosting GluN2B-NMDA signalling[46]. Traxoprodils, a GluN2B antagonisst, decreased depressive-like behaviours while reinforcing the antidepressant effects of standard MDD therapies such as desipramine, paroxetine, milnacipran, and bupropion[47].In short, shown fast antidepressant effects in clinical and preclinical data supports findings, albeit further clinical studies are needed to establish effectiveness. Targeting the GluN2B component of the NMDAR method providing immediate symptom relief might utilised as medications for those who are suicidal. More investigation into the pairing of NMDAR antagonists and SNRI or SSRI might provides fast-acting symptoms relief from the NMDAR antagonist as well as long-term antidepressants activity from the SSRI or SNRI. Further including such amantadine and memantines, will need to undergo thorough clinical trials to determine their suitability for treating.

4.3. Peroxisome Proliferator-Activated Receptors

Peroxisomes proliferators involved in lipid metabolism, glucose control, energy balance, and inflammation. Because PPAR is engaged in neurogenesis as well as cellular and behavioural functions that are linked to depression, regulating PPAR might be a significant therapeutic path for future study[48]. The generation of PPAR agonists must be treated seriously. Combination therapy should be investigated even more clinically, those who are already on an SNRI, SSRI, or statin might benefited from integrating a PPARs agonist into existing regimen.

4.4. GPR39 (G-Protein-Coupled Receptor)

MDD is related to zinc insufficiency and reduced expressions of the zinc sensings receptors G-proteins coupled receptors 39 (GPR39). When compared to acutes treatments of imipraminee, the NMDAR antagonists MK-801 or the $ZnCl_2$, the GPR39 agonists TC-G 1008 caused persistent antidepressant-like effects[49]. Ghrelin is a hungers hormones and an endogenous GPR39 agonists. In rats, ghrelin treatment decreased neuroinflammation and relieved depressive-like behaviours caused by myocardial infarction[50]. These findings suggest that increasing zinc[51] or manipulating zinc sensing receptors might be effective treatments for MDD.

4.5. Metabotropic Glutamate Receptors (mGluRs)

Metabotropics glutamates regulate glutamates discharge via second messengers mechanisms. Antidepressant potential has been demonstrated by targeting particular subtypes of mGluRs. The mGluR5 receptor is present in the postsynaptic membrane and is responsible for regulating plasticity and synaptic excitability. mGluR5 was discovered to have a significant depressions by regulating paired-pulses activations and modulating ketamine's fast antidepressant action[52].SNC and Rubiscolin-6 interact with said dopamine receptor family's nociceptin region to attenuate depressive-like behaviours in depression mouse models (NOPr). Tianaeptine reduced depressive-like behaviour in mice, and systemic inflammation in the prefrontal cortex (PFC) and hippocampus influenced energy and energy metabolism in a positive way. There's also the prospect of creating drugs that target particular opioid receptors to treat MDD.

5. Novel Antidepressants and treatments

There are various newer therapeutic alternatives available, such as desvenlafaxine, vortioxetine, vilazodone, and levomilnacipran, all of which have antidepressant effects via different neurochemical mechanisms. Desvenlafaxine, a venlafaxine active metabolite, is an SNRI authorised by the Foods and Drugs Administrations (FDA) in 2009 for the MDD treatment in adults. It is given in the form of desvenlafaxine succinate. The FDA authorised Vortioxetine for the treatment of MDD in 2013. It is an immediate-release pill containing the betas polymorphs of vortioxetine hydrobromide. Vilazodone, an SSRI and partial $5HT_{1A}$ receptor

agonist, was licenced by the FDA in 2011 for the MDD treatment in adults. The FDA has authorised levomilnaciprans ER, 1S, and 2R-milnacipran as an SNRI for the treatment of MDD in adults. Table 2 summarises the demographic features, dosage ranges, and length of trials of Desvenlafaxine, Levomilnacipran E, Vilazodone and Vortioxetine in patients, where RCT stands for randomised controlled trial and OLT stands for open-label study. As a result, table 3 summarises the overview of clinical results from research.

The multimodals mechanisms of action of novel antidepressants indicate that depressions would not be induced by a simple serotonins deficiency, but rather by serotonin itself "flooding" $5HT_{1A}$autoreceptors in midbrains peri-raphes regions via the actions of noradrenaline, glutamate and histamine. There has been minimal study on the usage of new antidepressants in humans, and additional research is needed to reveal significant differences and other unique features of these new drugs.

Depressive-like Receptors

Depressive-like behaviour was more common in those who have mGluR5. In mice, restoring mGluR5 activity in the amygdala reduced depressed behaviours. The ability to cope with adversity plays a key deciding whether stress leads to depression. Although linked to development of depression, the impact of its activation has yet to be investigated. Following access to diverse stressful stimuli, demonstrated more depression-like behaviours. In mGluR5/ mice, amygdala reduced these depression-like behaviours. Stress unable to induce FosB, whose activation increases stress resistance in the NAc, in mGluR5/ animals. FosB expression was enhanced after chemical stimulation of mGluR5 in the NAc. Reduced tension morbidly depressed responses by decreasing the expression BDNF in the brain. Ibuprofen, a neutral anti-inflammatory medication, inhibits COX-1 (NSAID). The medical number of respondents of depressed people who were given a mixture of ibuprofen and tetracycline improved dramatically, indicating that the antidepressants were more effective. reduces 86 specifically, which has been found to help

The mGluR5 stress resistance and survival [63]. This research highlights the importance transcription in stress resilience, as well as possibility addressing an antidepressant mechanism. There was no difference between adjunctive basimglurant MR and placebo major endpoint, physician MADRS improvement from baseline to end of therapy. On the other hand, had an antidepressant impact on secondary end goals.Together the compound, suggest that it should be studied further in depression symptoms [64]. LY341495[65] and LY3020371 [66] generated antidepressant impacts in mice by inhibiting the action deleterious[67] had the same antidepressant effect but with less side effects can also be used as an adjuvant or in combination with ketamine-based antidepressant treatment to lessen adverse effects while maintaining ketamine's effectiveness [68]. Enhance prefrontal brain (PFC) glutamate transmission, producing fast antidepressant-like effects.

To test the theory that selective inhibition of mGlu2 or mGlu3 intensifies PFC excitatory transmission and imparts antidepressant effectiveness in preclinical models, we used recently synthesised negativity. We discovered that systemic administration of a mGlu2 or mGlu3 NAM activated biophysically distinct PFC neuronal cell ensembles quickly. Mechanistic investigations demonstrated that mGlu2 and mGlu3 NAMs have mechanistically unique presynaptic and postsynaptic effects that increase thalamocortical communication and reduce long-term depression.

Stress Models

In two separate chronic stress models, systemic therapy with each NAM reduced passive coping and reversed anhedonia, indicating that both mGlu2 and mGlu3 NAMs generate antidepressant-like effects via similar but different modes of action[69].We employed freshly synthesised negativity to test the idea that selective inhibition of mGlu2 or mGlu3 enhances PFC excitatory transmission and confers antidepressant efficacy in preclinical animals. Systemic injection of a mGlu2 or mGlu3 NAM activated biophysically diverse PFC neuronal cell ensembles immediately, according to our findings. Mechanistic studies revealed that mGlu2 and mGlu3 NAMs have distinct presynaptic and postsynaptic actions that improve thalamocortical connectivity and prevent long-term depression.

The heterogeneous methods of operation of new antidepressants suggest that depressions are caused by

serotonin filling autoreceptors in the brainstem and peri-raphes areas via the activities of noradrenaline, glutamate, and histamine, rather than by a simple serotonin deficit. There has been very little investigation antidepressants in people, investigation is necessary uncover major differences and other distinguishing characteristics of these new medications.

Treatment for depressive-like behaviours

Galanin is a neuropeptide distinct and in CNS neurons. Signalling is mediated by GALR2, whereas inhibitory signalling is mediated by GALR1 and GALR3. GALR2 activation is antidepressant, but GALR1 and GALR3 activation increases depressive-like behaviours. Serotonin (5-HT) and galanin are co-expressed by around 40% of neurons, routes help with acquired stress, whereas nucleus accumbens. Improved inhibitory avoidance in the ETM, but the activation of GAL2 receptors by AR-M1896 (3.0 nmol) hindered it, implying had no effect on ETM escape behaviour or open-field locomotor activity. Prior treatment of WAY100635 (0.18 nmol), a 5-HT1A antagonist, reduced the anxiolytic effect of AR-M1896. Galanin (0.3 nmol) administered in the DRN increased discreetly flight behaviours induced by electrical stimulation of the DPAG, suggesting a panicolytic effect. Together, our results showed that galanin mediates opposite anxiety responses in the DRN by activation of GAL1 and GAL2 receptors.

The anxiolytic impact of Gal2 receptor activation may be influenced by, function is unknown [70]. By binding to the GALR1-GALR2 heterodimer, GAL(1–15) enhanced depressive-like behaviours in mice[71]. However, in conjunction with GAL(1–15), injection[72] decreased depressive-like behaviours[7374]. Exacerbated depressed behaviours, whereas[75] internet - based online analogue induced antidepressant effects. The release of cytokines causes a rise activity, which the production [76]. Lumiracoxib, a COX-2 inhibitor, reduced anxiety-like behaviours in mice by normalising corticosterone-induced glutamatergic currents in the amygdala[77]8g]. Characteristics caused antidepressant-like effects and reduced oxidative stress-induced inflammatory factor production [78].

COX-1 and COX-2 antagonists have both been shown to be beneficial in lowering depression symptoms in clinical trials. In chronic pain sufferers, diclofenac decreased depressed symptoms [79]. Reducing depressive symptoms in patients when given in combination[80]. Antidepressant effects have been linked[81].

Inhibitors of COX-1 and COX-2 were both found in clinical studies to be reduced. When taken in combination, celecoxib, a selective COX-2 inhibitor, was observed to reduce depression symptoms in patients. The effects of antidepressants have been connected.By downregulating BDNF in the hippocampus [82], ibuprofen decreased[83] stress-induced depressive-like behaviours[84]. COX-1 is inhibited by aspirin, a nonsteroidal anti-inflammatory drug (NSAID). The clinical response rate of depressed individuals treated with a combination of aspirin and minocycline improved significantly, showing boost antidepressant effectiveness[85]. decreases selectively [86], which has been shown to improve.

Stress-induced effects

Ibuprofen reduced stress-induced depressive-like behaviours through downregulation of BDNF in the hippocampus. The clinical response rate of depressed people treated with a combination of aspirin and minocycline increased considerably, indicating that the antidepressant efficacy was boosted. Lowers, which has been demonstrated to improve.Intriguingly, had antidepressant effects in older people [87], suggesting that this medication has limits that need to be explored further. Signalling and were suppressed by infliximab, a TNF antagonist[88]. modulates CRP IL-6 to have neuroprotective benefits and relieve depression symptoms [898390].

Fascinatingly, showed antidepressant properties in older persons, suggesting that this medicine has limitations that need to be further investigated. Infliximab, a TNF antagonist, decreased signalling. CRP IL-6 modulation has been shown to have neuroprotective properties and to alleviate depressive symptoms. Inflammatory drugs such for rheumatoid arthritis, and hidradenitis suppurativa (adalimumab for hidradenitis suppurativa. an antioxidant, were administered and shown to reduce depressive-like behaviours and restore corticosterone levels in the amygdala. Neuroprotection was also provided by NAC's antioxidant and anti-

inflammatory effects. Due to its features, modafinil, an anti-epileptic medicine, has also been demonstrated to have neuroprotective properties.

The link between illnesses and depression is significant, highlighting the function of depression and the intricate interplay between the two Inflammatory medications such as [9192939495] for rheumatoid arthritis), and hidradenitis suppurativa (adalimumab[96] for hidradenitis suppurativa. an antioxidant, was given and was found to attenuate depressive-like behaviours and restore corticosterone levels in the amygdala[97]. NAC antioxidant and anti-inflammatory properties also offered neuroprotection [98]. Modafinil, an anti-epileptic drug, has also been shown to have neuroprotective qualities due to characteristics [99].Significant link between disorders, depression highlights role in depression complex relationship[100]. To avoid depression as a comorbidity, it's important to use the right antiinflammatory drugs to treat chronic inflammatory illnesses. For acute inflammatory reasons, it may also be recommended to minimise systemic inflammation to avoid the development of depressed symptoms [101].

Anti-inflammatory drugs should be investigated further in depression cases without inflammatory illness to minimise elevated baseline inflammatory levels. possible treatment methods for a wide range of patients [102]. One reason certain persons are more prone to MDD than others might be the inflammatory system's specific response.The stress response mediated by HPA axis, a key neuroendocrine system in the CNS [103]. In the positive feedback loop, prolonged stress may lead to hyperactivation and increased synthesis, implying that inhibiting significant element avoiding stress-induced depression[104]. People with specific vulnerable to early life stresses or exhibit sensitivity resistance[105106].

Chronic stress suppresses MR expression, while antidepressants boost it. Increased MR reduces HPA axis activity, resulting in less anxiety and stress-coping mechanisms [107]. Executive function and memory were significantly improved in depressed individuals treated with fludrocortisone, an MR agonist. Importantly, this pathway stimulated MR without affecting adrenal cortisol output, which might have multiple and extensive negative consequences[108]. Spironolactone, an MR antagonist, reduced stress-induced activity and improved cognitive performance in patients[109], perhaps contributing to the development of MDD and brain pathology [110].

GRs regulates, which linked to depressive symptoms. mutant showed stress resistance[111] and antidepressant effectiveness was diminished[112]. With depressive-like behaviours generated by continuous restraint stress, FKBP5 mutant animals showed HPA axis suppression [113]. FKBP5 expression was shown to be linked to increased depressed symptoms and diminished antidepressant effectiveness in patients. In animal models, overexpression of GRs has been linked to stress resilience. When compared to rats with low GR expression, mice overexpressing MR were less likely to acquire helplessness tendencies [114]. Treatment with N-3 PUFAs alleviated depressed symptoms[115].

To build a complete, we cover the processes, behavioural consequences in this review[116]. OXT is most recognised involvement, but it a role behavioural, including behaviours. On a molecular level, a single receptor is responsible for all of OXT's aspects. It stimulates number signalling pathways, all of enhanced are all part of the cellular response to OXT. Anxiety and stress-regulating circuits in the brain are represented by OXTergic projections, which connect. The molecular backdrop of which OXT-induced patterns eventually modify an animal's or human's behaviour is still unknown and researching signalling first.In order to construct a holistic picture, we will go through the processes as well as the behavioural effects in this review. The most well-known engagement is OXT, however it is a behavioural function that includes behaviours. A single transmitter is accountable for all characteristics of OXT on a molecular level, promotes a number signalling pathways, all of which are increased. OXTergic projections, chemical context in which OXT-induced patterns change an animal's or human's behaviour is unclear, thus signalling research comes next. [117118119120].

In reaction to the poor clinical success rate for medications that showed significant promise in animal tests meant to replicate psychiatric pathophysiology, most big pharmaceutical firms have pulled back or shut down their clinical neuroscience research projects. These setbacks have raised major questions regarding the importance of preclinical research in the discovery and assessment of novel psychiatric pharmacotherapies.

The goal of establishing "animal models" appears unattainable in the lack of a full knowledge of the neuroscience of mental diseases. The highlight for making preclinical research more useful in the drug development process.

Most prominent pharmaceutical companies have scaled back or stopped down clinical neuroscience research initiatives in response to the low clinical success rate for drugs that showed substantial promise in animal testing aimed to simulate psychiatric pathophysiology. These disappointments have generated serious doubts about the value of preclinical research in the development and evaluation of new mental pharmacotherapies. The objective of creating "animal models" looks unrealistic due to a lack of understanding of mental disorder neurobiology. The emphasis for improving the use of preclinical research in the drug development process. We address this problem by examining how recent advancements in neuroscience, along with new conceptual approaches, have transformed how we diagnose and treat common mental disorders.

We examine the consequences of these new techniques for simulating mental diseases in animals and argue that comprehensive evaluations of preclinical work should be required before psychiatric clinical trials can be conducted. Animal research is critical for understanding human psychopathology, and enhancing the predictive validity of animal models is vital for generating more effective mental disease therapies.

Several notable pharmaceutical companies have scaled back or stopped down clinical neuroscience research initiatives in response to the low clinical success rate for drugs that showed substantial promise in animal testing aimed to simulate psychiatric pathophysiology. These disappointments have generated serious doubts about the value of pharmaceutical development in the development and evaluation of new mental pharmacotherapies. The objective of creating "animal models" looks unrealistic due to a lack of understanding of mental disorder neurobiology. The emphasis for improving the use of preclinical research in the drug discovery process. The usefulness of pharmaceutical development in the delivery and evaluation of novel mental pharmacotherapies has been seriously questioned as a result of these setbacks. Because of a lack of knowledge of mental disease neurobiology, the goal of generating "animal models" appears impossible. Improvements in the utilisation of pharmaceutical development in the drug discovery process are a priority. We tackle this issue by looking at how recent brain imaging studies, combined with new methodological frameworks, have changed how we identify and cure prevalent psychological problems.

Improvements in the utilisation of pharmaceutical research inside the drug development process are a priority. We tackle this issue by looking at how recent new findings, along with new conceptual approaches, have changed how we identify and treat common mental illnesses. We look at the implications of these novel approaches for imitating mental illnesses in animals, and conclude that full preclinical analyses should be necessary before psychiatric clinical trials can be conducted. Understanding human psychopathology requires animal research, and improving the predictive ability of animal studies is crucial for developing more effective mental disorder therapeutics[94].

These disappointments have generated serious doubts about the value of preclinical research in the development and evaluation of new mental pharmacotherapies. The objective of creating "animal models" looks unrealistic due to a lack of understanding of mental disorder neuroscience. The emphasis is on improving the use of preclinical research in drug discovery and development.It is a top goal to improve the use of pharmaceutical research in the medication development process. We look at how recent new results, as well as new conceptual approaches, have transformed how we detect and treat prevalent mental diseases to address this issue. We consider the consequences of these innovative ways of simulating mental diseases in animals and suggest that thorough preclinical testing is required before conducting psychiatric clinical trials.

Animal research is necessary for understanding human psychopathology, and enhancing the prediction capacity of animal studies is critical for generating more effective mental illness therapies.Anxious temperament (AT) is a temperament that develops early in life and increases the chance of developing stress-related depression. Because anxiety and depression are prevalent often begin in infancy, a greater knowledge of the variables that contribute to their start in childhood will aid in the creation in nonhuman primates (NHPs) has been constructed, allowing researchers to better understand the brain systems and molecular pathways

that mediate AT development. Multimodal neuroimaging studies demonstrate changes in brain metabolism in the employed[118].

The discovery presence pleasant indicated was one of the major advances in the research of appetitive learning [121]. Annabis that comes in variety. The efficacy of treating depression was assessed among who received cultivated supplier. Patients gave cannabis for its overall effectiveness in treating depression to identify relationships between anxiolytic efficacy and chemotype. Increased anxiolytic action is linked to been linked to a reduction in anxiolytic action[122]. A number of studies have found aberrant people, implying relationship microbiota behaviours. By transferring a high microorganisms, faecal microbiota transplant might change into, thereby improving behavioural. Conducted, which included colon suppressor, a faecal found that all improved significantly. They provide the results of a two-year follow-up with the same 18 subjects who had finished therapy. Notably, the majority of GI symptoms decreased when therapy ended. At follow-up, significant alterations in gut microbiota, Bifdobacteria, remained.

Their findings confirm MTT's prospective for issues, they call for future. Neuro-stimulation techniques have evolved into viable therapeutic modalities mental illnesses, particularly who have failed to other treatments. Repeated electroconvulsive therapy (ECT) operations are among them. This review discusses the role of neuro-stimulation technologies in the treatment of anxiety disorders. The modalities of various neuro-stimulation techniques are briefly discussed. The evidence for employing these tactics to treat anxiety disorders is investigated in further detail. The report then goes on to talk about the challenges of doing research on the usage of neuro-stimulation therapy in people who have anxiety disorders. Future research objectives are outlined in the review, with the goal of expanding the evidence base for anxiety disorder therapy and presenting neuro-stimulation approaches as a viable, effective, and acceptable choice in particular situations[123].

Over years, neuro-stimulation techniques have grown into promising therapeutic modalities for the treatment of mental diseases, particularly treatment resistant patients. Electroconvulsive treatment (ECT), repeated procedures are among them. The role of neuro-stimulation methods in the treatment of anxiety disorders is discussed in this review. The various neuro-stimulation methods' modes are briefly explored.The evidentiary foundation for using these strategies to treat anxiety disorders is examined in further depth. The paper then goes on to discuss the difficulties in conducting research on the use of neuro-stimulation treatments in individuals with anxiety disorders. The review outlines future research initiatives with the goal of extending the evidence basis for anxiety disorder therapy and presenting neuro-stimulation methods as a potential, effective, and acceptable option in specific instances [124].

Open-label therapy with drug company chamomile extract 1,500 was given to subjects with mild to severe GAD. Improvement ratings were primary objectives, were used as secondary outcomes [125]. Immune-kynurenine route has been shown to have anxiety-modulating effects, according to growing research. Stress or inflammation disrupt also serve as endogenous anxiogens, causing or maintaining stress.[126]The immune-kynurenine route has been shown to have anxiety-modulating effects, according to growing research. Stress or inflammation disrupt causing shortage and also operate, all of which can generate or perpetuate anxiety [127]. Recent research suggests that small basal forebrain area, may offer vital insights into diagnosing and addressing depression and anxiety. According to convergent studies, have complimentary separate functions specialising danger to sustain, and responding unpleasant stimuli mostly motivated dangers or may not arise in the future [128].

In effectiveness studies, cognitive behavioural treatment (CBT) has long-term impact in kids with depression and anxiety. However, effects environment remain unknown [129].Treatment depressive symptoms and depression require a wide range of options, as well as the risk of undesirable side effects for patients, such as anxiety and sadness. Therapy methods may have properties similar to benzodiazepines. The goal of this study is to investigate if cutting-edge treatments for resistant depression and refractory severe depression can lead to dependence. We looked through the following databases: Although it is effective in treating severe depression, long-term use has been associated to the development of addiction. Although there is a danger of overuse, stimulant medication augmentation is often beneficial for lingering depressed symptoms. Despite

a lack of evidence and the risk of patients becoming reliant, a wide range of illnesses including depression are being treated fast. To summarise, benzodiazepines, ketamine, stimulant medications, and marijuana all have some characteristics, such as short-term benefits and the possibility for sustained pharmaceutical use. Therapies raises the question of whether or not it is necessary to provide these medications.

The diagnostic accuracy and clinical value of ICD-11 were comparable to or better than that of ICD-10. When utilising ICD-11, global physicians were much more accurate in identifying Depression or Anxiety, and these diseases received excellent clinical usefulness ratings. Clinicians also regarded the ICD-11 recommendations to be user-friendly, straightforward, and well-suited to the patients they face in their practises. Clinicians, on the other hand, struggled to discern normalcy in episodes, as well as to apply the standards [130].

Therapy-resistant mood disorders

Therapy-resistant mood disorders and depression need extensive choices must with side possible negative consequences for patients, such as newest anxiety and depression therapy techniques may have features comparable to benzodiazepines. study see if innovative techniques resistant depression and refractory major depression may lead to dependency. The following databases were searched: useful alleviating the serious depression, it has long-term usage has been linked to the development of addiction. Stimulant drug augmentation is typically useful for residual depressive symptoms, although lived risk of misuse. rapidly variety ailments and depression, despite a lack of proof and the danger of patients acquiring dependent. In conclusion, benzodiazepines, ketamine, stimulant drugs, and marijuana all have some features, such as short-term advantages potential pharmaceutical continued usage. Therapies questions whether providing these drugs to people with depression and anxiety disorders is justified in the long term[131].

The lack of PTSD psychpharmacology research might be due to a number of factors. Focus of research since these funds are viewed, minor originality. Aid clinical trial investigators in determining the appropriate pharmaceutical dosage. Furthermore, academics may assume that creating cooperation sector encourage novel RCTs will be difficult due to concerns about intellectual property. These findings might help individuals with serious depression normalise their amygdala activation and negative mood states [132].There are several possible explanations for the paucity of PTSD psychopharmacology research. Clinical trial applications are being submitted by a small number of PTSD psychopharmacology experts.

Because these funding may be seen as being of minimal novelty, frequently drugs drive investigations, help clinical trial investigators choose the best medication dosage. Furthermore, because of worries about intellectual property, academics may believe that forming collaborations sector that promote innovative RCTs will be challenging. Elevation of research since these funds are looked, lower originality. Clinical trial investigators in determining the appropriate pharmaceutical dosage. Table 5 displays the neuroprotective characteristics of antidepressants in cellular and animal research. Furthermore, academics may assume that creating cooperation sector will be difficult due to concerns about intellectual property.

Because these monies are seen as being of minimal uniqueness, testing of routinely given but unvalidated drugs may not be the focus of study. There may be a paucity of data on pharmacological and physiological characteristics, targeting activation, help clinical trial investigators choose the right medication dosage. Furthermore, academics may believe that establishing collaboration among funding bodies will be challenging owing issues. Collaboration across the governmental, industrial, scientific, and therapeutic sectors to deal with the current crisis cannot be underestimated. [133].The hops plant medicine for depression problems. Goal see how affected young individuals' sadness. Table 4 shows that antidepressant function of ethnobotanical plants: mechanism(s) of action and phytochemical compounds At the start and conclusion, anthropometric measures, DASS-21 evaluations, and morning cortisol plasma levels were measured, all p values[134].

Conclusion

MDD was the target of the first monoamine-based antidepressants. Ketamine and its equivalents were recently approved as antidepressants with a short half-life. Unfortunately, the current therapeutic choices are insufficient; their lack of efficacy, risks, and side effects leave patients with few treatment options. Origins

developing new are now being pursued. In this study, we explore potential severe depressive disease, can produce antidepressant effects. The anti-inflammatory advantages of SNRIs and SSRIs in anti-depression treatment are highlighted in this study, as well as the individual causes of these concerns for each medicine. We also give an overview of depression, the processes that underpin it. Natural products, such as herbs, botanicals, and fatty acids, also helped to reduce depression-related behaviours and symptoms. This review will provide an overview of medically available antidepressants, with an emphasis on novel pharmacological approaches that have demonstrated potential antidepressant benefits in clinical and preclinical studies.

Conflict of interest statement: The authors declared no conflict of interest" in the manuscript.

Table 1. Inflammatory targets of the SSRI and SNRI in humans

Studies	Inflammatory substrate of action	SSRI/SNRI	Effect
Chen et al. (2018)[22]	TNFα protein level	Venlafaxine	↓
Gupta et al. (2017)[24]	TNFα protein level	Fluoxetine	↓
Carboni et al. (2019)[25]	TNFα protein level	Paroxetine	↑
Halaris et al. (2015)[26]	TNFα protein level	Escitalopram	No difference
Chen et al. (2018)[22]	IL-6 protein level	Paroxetine	↓
Halaris et al. (2015)[26]	IL-6 protein level	Escitalopram	No difference
Carboni et al. (2019)[25]	IL-6 protein level	Paroxetine	↑
Chen et al. (2018)[22]	IL-1β protein level	Venlafaxine	↓
Alcocer-Gomez et al. (2017)[23]	IL-1β protein level	Paroxetine	↓
Alcocer-Gomez et al. (2017)[23]	IL-1β protein level	Fluoxetine	↓
Halaris et al. (2015)[26]	IL-1β protein level	Escitalopram	No difference
Alcocer-Gomez et al. (2017)[23]	IL-1β protein level	Venlafaxine	↓
Alcocer-Gomez et al. (2017)[23]	NLRP3 inflammasome	Venlafaxine	↓
Alcocer-Gomez et al. (2017)[23]	NLRP3 inflammasome	Fluoxetine	↓
Alcocer-Gomez et al. (2017)[23]	NLRP3 inflammasome	Paroxetine	↓

Table 2. Studies of Desvenlafaxine, Levomilnacipran ER, Vilazodone and Vortioxetine

Related Works	Design	Groups(n)	Duration (weeks)	Age (years)	Dose range (mg)
Findling RL, et al., 2016[53]	OLT	59	8	7-17	10-200
Boyer P, et al., 2015[54]	RCT	Desvenlafaxine 100 mg=148 Desvenlafaxine 50 mg=166 Placebo=161	8	>18	50-100
Jacobsen PL, et al., 2015[55]	RCT	Vortioxetine 20 mg=150 Vortioxetine 10 mg=155 Placebo=157	8	18-75	10-20
Mahableshwarkar AR, et al., 2015[56]	RCT	Duloxetine=152 Vortioxetine 20 mg=154 Vortioxetine 15 mg=147 Placebo=161	6	18-75	Duloxetine=60 Vortioxetine=15,20

Related Works	Design	Groups(n)	Duration (weeks)	Age (years)	Dose range (mg)
Chen G, et al., 2015[57]	RCT	Warfarn and vortioxetine Aspirin and vortioxetine	2	18-45	Venlafaxine=10
Matthews M, et al., 2015[58]	RCT	Vilazodone 40 mg=291 Vilazodone 20 mg=292 Citalopram 40 mg=289 Placebo=290	10 Single dose	18-70 32-76	20-40
Grant JE, et al., 2017[59]	RCT	Citalopram 40 mg=23 Vilazodone 40 mg=19 Citalopram 20 mg=79	12	18-60	40
Croft HA, et al., 2015[60]	RCT	Vilazodone=253 Placebo=252	8	18-70	50
Chen L, et al., 2015[61]	OLT	Levomilnacipran ER Carbamezapine=34 Levomilnacipran ER Ketoconazole=34 Levomilnacipran ER Alprazolam=30	Variable	18-45	40-120
Chen L, et al., 2015[62]	OLT	32 in four groups based on RF	Single dose	32-76	

Table 3. A review of the clinical results of studies

Studies	Clinical outcomes
Findling RL, et al., 2016[53]	Des was considered safe and well-liked as a youngster. The AUC was discovered to b
Boyer P, et al., 2015[54]	Des 50 and 100 mg were more efficient than placebo for depressive symptoms and ov
Jacobsen PL, et al., 2015[55]	Vortioxetines 20 mg was found to be substantially more effective than placebo in trea
Mahableshwarkar AR, et al., 2015[56]	Vortioxetine 20 mg alleviated symptoms of depression and anxiety.
Chen G, et al., 2015[57]	Vortioxetine had no influence on the aspirin and warfarin steady-states pharmacokine
Matthews M, et al., 2015 [58]	When compared to placebo, vilazodone 20/40 mg had the same effectiveness and tole
Grant JE, et al., 2017[59]	Initials non-responders to citalopram appear to be comparably likely to respond to a
Croft HA, et al., 2015[60]	Vilazodone 40 mg/day produced statistically significant results when compared to pla
Chen L, et al., 2015[61]	Doses reductions with ketoconazoles is required, as is dose modification with CYP3A
Chen L, et al., 2015[62]	With mild renal impairment, no dosage modifications are required; however, adjustm

Table 4. Ethnological plants with antidepressant activity: mechanism(s) of action and phytochemical

substances

Plant	Plant's parts showing anti-depressant activity	Type of extract(s) used	Neutraceutical comp
Agapanthus campanulatus	Leaves, Flowers, Roots	Aqueous, Ethanolic	Flavonoids
Akebiae fructus	Fruit powder	Ethanolic	Hederagenin
Albizzia julibrissin	Stem bark	Ethanolic	Saponins
Allium cepa	Bulb powder	Aqueous	Quercetin glycosides

Table 5. Anti-depressant neuroprotective properties in cellular and animal studies.

Type	Operation
TBI	Wild-type
Deficiency of memory	Morris water maze challenge, step
Glucose intolerance and behavioural changes caused by chronic restriction stress (CRS)	Morris water testing of continuous

References

1. Elias E, Zhang AY, Manners MT. Novel Pharmacological Approaches to the Treatment of Depression. *Life*. 2022;12(2). doi:10.3390/life12020196 2. Köhler O, E. Benros M, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects a systematic review and meta-analysis of randomized clinical trials. *JAMA Psychiatry*. 2014;71(12):1381-1391. doi:10.1001/jamapsychiatry.2014.1611 3. Luan D, Zhao M-G, Shi Y-C, et al. Mechanisms of repetitive transcranial magnetic stimulation for anti-depression: Evidence from preclinical studies. *World J Psychiatry*. 2020;10(10):223-233. doi:10.5498/wjp.v10.i10.223 4. Al-Harrasi A, Csuk R, Khan A, Hussain J. Distribution of the anti-inflammatory and anti-depressant compounds: Incensole and incensole acetate in genus Boswellia. *Phytochemistry*. 2019;161(January):28-40. doi:10.1016/j.phytochem.2019.01.007 5. Nikkheslat N. Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency. *Brain, Behav Immun - Heal*. 2021;18(May):100383. doi:10.1016/j.bbih.2021.100383 6. Liu X jie, Wang Y ze, Wei F xiao, et al. The synergistic anti-depression effects of different efficacy groups of Xiaoyaosan as demonstrated by the integration of network pharmacology and serum metabolomics. *J Pharm Biomed Anal*. 2021;197:113949. doi:10.1016/j.jpba.2021.113949 7. Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders.*Pharmacol Ther*. 2019;204:107402. doi:10.1016/j.pharmthera.2019.107402 8. Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: From monoamines to glutamate. *Exp Clin Psychopharmacol*. 2015;23(1):1-21. doi:10.1037/a0038550 9. Hashimoto K. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. *Biochem Pharmacol*. 2020;177(February):113935. doi:10.1016/j.bcp.2020.113935 10. McEwen BS, Akil H. Revisiting the stress concept: Implications for affective disorders. *J Neurosci*. 2020;40(1):12-21. doi:10.1523/JNEUROSCI.0733-19.2019 11. Okano M, Takahata K, Sugimoto J, Muraoka S. Selegiline Recovers Synaptic Plasticity in the Medial Prefrontal Cortex and Improves Corresponding Depression-Like Behavior in a Mouse Model of Parkinson's Disease. *Front Behav Neurosci*. 2019;13. doi:10.3389/fnbeh.2019.00176 12. Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of Antidepressants on Sleep. *Curr Psychiatry Rep*. 2017;19(9):1-7. doi:10.1007/s11920-017-0816-4 13. @BLACKEAGLE34. Protest #justice4rash #justiceforrashan [tweet]. *twitter 28 July*. 2018;(5). doi:10.1002/14651858.CD010753.pub2.www.cochranelibrary.com 14. Shuto T, Kuroiwa M, Sotogaku N, et al. Obligatory roles of dopamine D1 receptors in the dentate gyrus in antidepressant actions of a selective serotonin reuptake inhibitor, fluoxetine. *Mol Psychiatry*. 2020;25(6):1229-1244. doi:10.1038/s41380-018-0316-x 15. Xu D, Wang C, Zhu X, et al. The antidepressant-like effects of fluvoxamine in mice involve the mTOR signaling in the hippocampus and prefrontal cortex. *Psychiatry Res*. 2020;285:112708. doi:10.1016/j.psychres.2019.112708 16. Laoutidis ZG, Kioulos KT. Desvenlafax-

ine for the Acute Treatment of Depression: A Systematic Review and Meta-analysis.*Pharmacopsychiatry*. 2015;48(6):187-199. doi:10.1055/s-0035-1555879 17. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological Treatments. *Can J Psychiatry*. 2016;61(9):540-560. doi:10.1177/0706743716659417 18. Ho PS, Yeh YW, Huang SY, Liang CS. A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram. *Psychoneuroendocrinology*. 2015;53(60):246-255. doi:10.1016/j.psyneuen.2015.01.008 19. Ghosh S, Choudhury S, Chowdhury O, et al. Inflammation-induced behavioral changes is driven by alterations in Nrf2-dependent apoptosis and autophagy in mouse hippocampus: Role of fluoxetine. *Cell Signal*. 2020;68(September 2019):109521. doi:10.1016/j.cellsig.2019.109521 20. Dai J, Pan JY, Liao N, et al. Influence of miR-155 on behaviors of depression mice through regulating Wnt/-catenin signaling pathway.*Eur Rev Med Pharmacol Sci*. 2020;24(3):1398-1407. doi:10.26355/eurrev_202002_20197 21. Zhao YW, Pan YQ, Tang MM, Lin WJ. Blocking p38 signaling reduces the activation of pro-inflammatory cytokines and the phosphorylation of p38 in the habenula and reverses depressive-like behaviors induced by neuroinflammation. *Front Pharmacol*. 2018;9(MAY):1-14. doi:10.3389/fphar.2018.00511 22. Chen CY, Yeh YW, Kuo SC, et al. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder. *Psychoneuroendocrinology*. 2018;87(325):108-118. doi:10.1016/j.psyneuen.2017.10.009 23. Alcocer-Gómez E, Casas-Barquero N, Williams MR, et al. Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder. *Pharmacol Res*. 2017;121:114-121. doi:10.1016/j.phrs.2017.04.028 24. Gupta K, Gupta R, Bhatia MS, Tripathi AK, Gupta LK. Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression. *J Clin Pharmacol*. 2017;57(12):1519-1526. doi:10.1002/jcph.963 25. Carboni L, McCarthy DJ, Delafont B, et al. Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. *Transl Psychiatry*. 2019;9(1). doi:10.1038/s41398-019-0521-7 26. Halaris A, Myint AM, Savant V, et al. Does escitalopram reduce neurotoxicity in major depression? *J Psychiatr Res*. 2015;66-67:118-126. doi:10.1016/j.jpsychires.2015.04.026 27. Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature*. 2016;533(7604):481-486. doi:10.1038/nature17998 28. Fukumoto K, Toki H, Iijima M, et al. Antidepressant potential of (R)-ketamine in rodent models: Comparison with (S)-ketamine. *J Pharmacol Exp Ther*. 2017;361(1):9-16. doi:10.1124/jpet.116.239228 29. Jiang C, Lin WJ, Labonté B, et al. VGF and its C-terminal peptide TLQP-62 in ventromedial prefrontal cortex regulate depression-related behaviors and the response to ketamine. *Neuropsychopharmacology*. 2019;44(5):971-981. doi:10.1038/s41386-018-0277-4 30. Fukumoto K, Iijima M, Funakoshi T, Chaki S. Role of 5-HT 1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine. *Int J Neuropsychopharmacol*. 2018;21(4):371-381. doi:10.1093/ijnp/pyx116 31. Pałucha-Poniewiera A, Podkowa K, Pilc A. Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats. *Behav Pharmacol*. 2019;30(6):471-477. doi:10.1097/FBP.0000000000000471 32. Rosa PB, Neis VB, Ribeiro CM, Moretti M, Rodrigues ALS. Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors. *Pharmacol Reports*. 2016;68(5):996-1001. doi:10.1016/j.pharep.2016.05.010 33. Zajecka JM, Stanford AD, Memisoglu A, Martin WF, Pathak S. Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: Results of a phase III clinical trial (FORWARD-3). *Neuropsychiatr Dis Treat*. 2019;15:795-808. doi:10.2147/NDT.S199245 34. Fava M, Thase ME, Trivedi MH, et al. Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. *Mol Psychiatry*. 2020;25(7):1580-1591. doi:10.1038/s41380-018-0284-1 35. Callaghan CK, Rouine J, Dean RL, et al. Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model. *Brain Behav Immun*. 2018;67:152-162. doi:10.1016/j.bbi.2017.08.016 36. Mitsumoto Y, Sato R, Tagawa N, Kato I. Rubiscolin-6, a σ-opioid peptide from spinach RuBisCo, exerts antidepressant-like effect in restraint-stressed mice. *J Nutr Sci Vitaminol (Tokyo)*. 2019;65(2):202-204. doi:10.3177/jnsv.65.202 37.

Park JY, Chae S, Kim CS, et al. Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists. *Korean J Physiol Pharmacol.* 2019;23(6):427-448. doi:10.4196/kjpp.2019.23.6.427 38. Trojan E, Chamera K, Bryniarska N, et al. Correction to: Role of Chronic Administration of Antidepressant Drugs in the Prenatal Stress-Evoked Inflammatory Response in the Brain of Adult Offspring Rats: Involvement of the NLRP3 Inflammasome-Related Pathway (Molecular Neurobiology, (2019), 56, 8, (. *Mol Neurobiol.* 2019;56(8):5381. doi:10.1007/s12035-019-1534-1 39. Poleszak E, Wośko S, Sławińska K, et al. Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice. *Pharmacol Biochem Behav.* 2020;188(September 2019). doi:10.1016/j.pbb.2019.172833 40. Ramoz N, Hoertel N, Nobile B, et al. Corticotropin releasing hormone receptor CRHR1 gene is associated with tianeptine antidepressant response in a large sample of outpatients from real-life settings. *Transl Psychiatry.* 2020;10(1). doi:10.1038/s41398-020-01067-y 41. Liu W, Li Q, Ye B, et al. Repeated Nitrous Oxide Exposure Exerts Antidepressant-Like Effects Through Neuronal Nitric Oxide Synthase Activation in the Medial Prefrontal Cortex. *Front Psychiatry.* 2020;11(September):1-11. doi:10.3389/fpsyt.2020.00837 42. Nagele P, Duma A, Kopec M, et al. Nitrous oxide for treatment-resistant major depression: A proof-of-concept trial. *Biol Psychiatry.* 2015;78(1):10-18. doi:10.1016/j.biopsych.2014.11.016 43. Lavretsky H, Laird KT, Krause-Sorio B, et al. A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. *Am J Geriatr Psychiatry.* 2020;28(2):178-190. doi:10.1016/j.jagp.2019.08.011 44. Yang B, Ren Q, Ma M, Chen QX, Hashimoto K. Antidepressant effects of (+)-MK-801 and (-)-MK-801 in the social defeat stress model. *Int J Neuropsychopharmacol.* 2016;19(12):1-5. doi:10.1093/ijnp/pyw080 45. Rana P, Bagewadi H, Banerjee BD, Bhattacharya SK, Mediratta PK. Attenuation of oxidative stress and neurotoxicity involved in the antidepressant-like effect of the MK-801(dizocilpine) in Bacillus Calmette-Guerin-induced depression in mice. *J Basic Clin Physiol Pharmacol.* 2020;31(4):1-10. doi:10.1515/jbcpp-2019-0016 46. Pothula S, Liu RJ, Wu M, et al. Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons. *Neuropsychopharmacology.* 2021;46(4):799-808. doi:10.1038/s41386-020-00882-7 47. Poleszak E, Stasiuk W, Szopa A, et al. Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice. *Metab Brain Dis.* 2016;31(4):803-814. doi:10.1007/s11011-016-9810-5 48. Matrisciano F, Pinna G. PPAR and functional foods: Rationale for natural neurosteroid-based interventions for postpartum depression. *Neurobiol Stress.* 2020;12(April):100222. doi:10.1016/j.ynstr.2020.100222 49. Starowicz G, Jarosz M, Frackiewicz E, et al. Long-lasting antidepressant-like activity of the GPR39 zinc receptor agonist TC-G 1008. *J Affect Disord.* 2019;245(November 2018):325-334. doi:10.1016/j.jad.2018.11.003 50. Sun N, Mei Y, Hu Z, et al. Ghrelin attenuates depressive-like behavior, heart failure, and neuroinflammation in postmyocardial infarction rat model. *Eur J Pharmacol.* 2021;901(April):174096. doi:10.1016/j.ejphar.2021.174096 51. Wang J, Um P, Dickerman BA, Liu J. Zinc, magnesium, selenium and depression: A review of the evidence, potential mechanisms and implications. *Nutrients.* 2018;10(5):1-19. doi:10.3390/nu10050584 52. Wang Y, He W, Zhang H, et al. mGluR5 mediates ketamine antidepressant response in susceptible rats exposed to prenatal stress. *J Affect Disord.* 2020;272(October 2019):398-408. doi:10.1016/j.jad.2020.03.104 53. Findling RL, Groark J, Tourian KA, et al. Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder. *J Child Adolesc Psychopharmacol.* 2016;26(10):909-921. doi:10.1089/cap.2016.0009 54. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. *Int Clin Psychopharmacol.* 2008;23(5):243-253. doi:10.1097/YIC.0b013e32830cebed 55. Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. *J Clin Psychiatry.* 2015;76(5):575-582. doi:10.4088/JCP.14m09335 56. Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. *J Clin Psychiatry.* 2015;76(5):583-591. doi:10.4088/JCP.14m09337 57. Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. *J Clin Phar-*

macol. 2015;55(6):671-679. doi:10.1002/jcph.456 58. Mathews M, Gommoll C, Chen D, Nunez R, Khan A. Efficacy and safety of vilazodone 20 and 40mg in major depressive disorder: A randomized, double-blind, placebo-controlled trial. *Int Clin Psychopharmacol*. 2015;30(2):67-74. doi:10.1097/YIC.0000000000000057 59. Grant JE, Redden SA, Leppink EW. Double-blind switch study of vilazodone in the treatment of major depressive disorder. *Int Clin Psychopharmacol*. 2017;32(3):121-126. doi:10.1097/YIC.0000000000000166 60. Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: A randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2014;75(11):e1291-e1298. doi:10.4088/JCP.14m08992 61. Chen L, Greenberg WM, Brand-Schieber E, Wangsa J, Periclou A, Ghahramani P. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. *Drug Des Devel Ther*. 2015;9:3293-3300. doi:10.2147/DDDT.S85418 62. Chen L, Boinpally R, Gad N, et al. Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects. *Clin Drug Investig*. 2015;35(10):601-612. doi:10.1007/s40261-015-0318-2 63. Shin S, Kwon O, Kang JI, et al. mGluR5 in the nucleus accumbens is critical for promoting resilience to chronic stress. *Nat Neurosci*. 2015;18(7):1017-1024. doi:10.1038/nn.4028 64. Quiroz JA, Tamburri P, Deptula D, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: A randomized clinical trial. *JAMA Psychiatry*. 2016;73(7):675-684. doi:10.1001/jamapsychiatry.2016.0838 65. Pałucha-Poniewiera A, Podkowa K, Rafało-Ulińska A. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice. *Prog Neuro-Psychopharmacology Biol Psychiatry*. 2021;109(December 2020). doi:10.1016/j.pnpbp.2020.110239 66. Witkin JM, Mitchell SN, Wafford KA, et al. Comparative effects of LY3020371, a potent and selective metabotropic glutamate (mGlu) 2/3 receptor antagonist, and ketamine, a noncompetitive N-methyl-D-aspartate receptor antagonist in rodents: Evidence supporting the use of mGlu2/3 antagonists, for the. *J Pharmacol Exp Ther*. 2017;361(1):68-86. doi:10.1124/jpet.116.238121 67. Joffe ME, Santiago CI, Oliver KH, et al. mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects. *Neuron*. 2020;105(1):46-59.e3. doi:10.1016/j.neuron.2019.09.044 68. Zanos P, Highland JN, Stewart BW, et al. (2R,6R)-hydroxynorketamine exerts mGlu2 receptordependent antidepressant actions. *Proc Natl Acad Sci U S A*. 2019;116(13):6441-6450. doi:10.1073/pnas.1819540116 69. Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature*. 2016;533(7604):481-486. doi:10.1038/nature17998 70. Morais JS, Souza MM, Campanha TMN, et al. Galanin subtype 1 and subtype 2 receptors mediate opposite anxiety-like effects in the rat dorsal raphe nucleus. *Behav Brain Res*. 2016;314:125-133. doi:10.1016/j.bbr.2016.08.007 71. Millón C, Flores-Burgess A, Narváez M, et al. Galanin (1–15) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: involvement of the raphe-hippocampal 5-HT neuron system.*Brain Struct Funct*. 2016;221(9):4491-4504. doi:10.1007/s00429-015-1180-y 72. Flores-Burgess A, Millón C, Gago B, et al. Galanin (1-15) enhancement of the behavioral effects of Fluoxetine in the forced swimming test gives a new therapeutic strategy against depression.*Neuropharmacology*. 2017;118:233-241. doi:10.1016/j.neuropharm.2017.03.010 73. Flores-Burgess A, Millón C, Gago B, et al. *Galanin (1–15)-Fluoxetine Interaction in the Novel Object Recognition Test. Involvement of 5-HT1A Receptors in the Prefrontal Cortex of the Rats*. Vol 155.; 2019. doi:10.1016/j.neuropharm.2019.05.023 74. Funck VR, Fracalossi MP, Vidigal APP, Beijamini V. Dorsal hippocampal galanin modulates anxiety-like behaviours in rats.*Brain Res*. 2018;1687:74-81. doi:10.1016/j.brainres.2018.02.036 75. de Souza MM, Silote GP, Herbst LS, Funck VR, Joca SRL, Beijamini V. The antidepressant-like effect of galanin in the dorsal raphe nucleus of rats involves GAL 2 receptors. *Neurosci Lett*. 2018;681(April):26-30. doi:10.1016/j.neulet.2018.05.029 76. Sokol CL, Luster AD. The chemokine system in innate immunity.*Cold Spring Harb Perspect Biol*. 2015;7(5):1-20. doi:10.1101/cshperspect.a016303 77. Morgan A, Kondev V, Bedse G, Baldi R, Marcus D, Patel S. Cyclooxygenase-2 inhibition reduces anxiety-like behavior and normalizes enhanced amygdala glutamatergic transmission following chronic oral corticosterone treatment. *Neurobiol Stress*. 2019;11(April):100190. doi:10.1016/j.ynstr.2019.100190 78. Guo J, Zhang F, Gao J, et al. Proteomics-based screening of the target proteins associated with antidepressant-like effect and mechanism of Saikosaponin A. *J Cell Mol Med*. 2020;24(1):174-188. doi:10.1111/jcmm.14695

79. Jafarinia M, Afarideh M, Tafakhori A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. *J Affect Disord*. 2016;204:1-8. doi:10.1016/j.jad.2016.05.076 80. Majd M, Hashemian F, Hosseinib SM, Shariatpanahi MV, Sharifid A. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in treatment of drug-naive depressed women: A pilot study. *Iran J Pharm Res*. 2015;14(3):891-899. 81. Lostutter T.W., Lewis M.A.,Concronce JM., Neighbors C. LM. 基因的改变NIH Public Access. *Bone*. 2014;23(1):1-7. doi:10.1016/j.jsb.2014.11.005.THE 82. Seo MK, Lee JG, Park SW. Effects of escitalopram and ibuprofen on a depression-like phenotype induced by chronic stress in rats. *Neurosci Lett*. 2019;696:168-173. doi:10.1016/j.neulet.2018.12.033 83. Zazula R, Husain MI, Mohebbi M, et al. Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. *Aust N Z J Psychiatry*. 2021;55(8):784-798. doi:10.1177/0004867420965697 84. Nozari M, Nahavandi A, Zeinivand M, et al. Research paper: Ibuprofen protection against restrained chronic stress-induced depression in male rats. *Basic Clin Neurosci*. 2020;11(4):413-421. doi:10.32598/bcn.11.4.1775.2 85. Savitz JB, Teague TK, Misaki M, et al. Treatment of bipolar depression with minocycline and/or aspirin: An adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. *Transl Psychiatry*. 2018;8(1). doi:10.1038/s41398-017-0073-7 86. Angiolillo DJ, Weisman SM. Clinical Pharmacology and Cardiovascular Safety of Naproxen. *Am J Cardiovasc Drugs*. 2017;17(2):97-107. doi:10.1007/s40256-016-0200-5 87. Berk M, Woods RL, Nelson MR, et al. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. *JAMA Psychiatry*. 2020;77(10):1012-1020. doi:10.1001/jamapsychiatry.2020.1214 88. Mansur RB, Delgado-Peraza F, Subramaniapillai M, et al. Extracellular Vesicle Biomarkers Reveal Inhibition of Neuroinflammation by Infliximab in Association with Antidepressant Response in Adults with Bipolar Depression. *Cells*. 2020;9(4):1-17. doi:10.3390/cells9040895 89. Murrough JW, Huryk KM, Mao X, et al. A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. *J Affect Disord*. 2018;230(January):56-64. doi:10.1016/j.jad.2017.12.067 90. Chakraborty S, Tripathi SJ, Raju TR, Shankaranarayana Rao BS. Mechanisms underlying remediation of depression-associated anxiety by chronic N-acetyl cysteine treatment. *Psychopharmacology (Berl)*. 2020;237(10):2967-2981. doi:10.1007/s00213-020-05585-x 91. Nettis MA, Lombardo G, Hastings C, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. *Neuropsychopharmacology*. 2021;46(5):939-948. doi:10.1038/s41386-020-00948-6 92. Reich K, Foley P, Han C, et al. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. *J Dermatolog Treat*. 2020;31(6):617-623. doi:10.1080/09546634.2019.1628172 93. Kim SJ, Park MY, Pak K, et al. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and 18fluorodeoxyglucose (FDG) positron emi. *J Dermatolog Treat*. 2018;29(8):761-768. doi:10.1080/09546634.2018.1466021 94. Brymer KJ, Fenton EY, Kalynchuk LE, Caruncho HJ. Peripheral etanercept administration normalizes behavior, hippocampal neurogenesis, and hippocampal reelin and GABAA receptor expression in a preclinical model of depression. *Front Pharmacol*. 2018;9(FEB):1-13. doi:10.3389/fphar.2018.00121 95. Tiosano S, Yavne Y, Watad A, et al. The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis. *Eur J Clin Invest*. 2020;50(9):0-2. doi:10.1111/eci.13268 96. Scheinfeld N, Sundaram M, Teixeira H, Gu Y, Okun M. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. *Dermatol Online J*. 2016;22(3). doi:10.5070/d3223030360 97. Menke A. Is the HPA axis as target for depression outdated, or is there a new hope? *Front Psychiatry*. 2019;10(FEB):1-8. doi:10.3389/fpsyt.2019.00101 98. Fan C, Long Y, Wang L, et al. N-Acetylcysteine Rescues Hippocampal Oxidative Stress-Induced Neuronal Injury via Suppression of p38/JNK Signaling in Depressed Rats. *Front Cell Neurosci*. 2020;14(November):1-11. doi:10.3389/fncel.2020.554613 99. Han J, Chen D, Liu D, Zhu Y. Modafinil attenuates inflammation via inhibiting Akt/NF-ϰB pathway in apoE-deficient mouse model of atherosclerosis. *Inflammopharmacology*. 2018;26(2):385-393. doi:10.1007/s10787-017-0387-3 100. Beurel E, Toups M, Nemeroff CB. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. *Neuron*. 2020;107(2):234-256.

doi:10.1016/j.neuron.2020.06.002 101. Kohler O, Krogh J, Mors O, Eriksen Benros M. Inflammation in Depression and the Potential for Anti-Inflammatory Treatment. *Curr Neuropharmacol*. 2016;14(7):732-742. doi:10.2174/1570159x14666151208113700 102. Lotrich FE. Inflammatory cytokine-associated depression.*Brain Res*. 2015;1617:113-125. doi:10.1016/j.brainres.2014.06.032 103. Keller J, Gomez R, Williams G, et al. HPA axis in major depression: Cortisol, clinical symptomatology and genetic variation predict cognition. *Mol Psychiatry*. 2017;22(4):527-536. doi:10.1038/mp.2016.120 104. Lotan A, Lifschytz T, Mernick B, et al. Alterations in the expression of a neurodevelopmental gene exert long-lasting effects on cognitive-emotional phenotypes and functional brain networks: Translational evidence from the stress-resilient Ahi1 knockout mouse.*Mol Psychiatry*. 2017;22(6):884-899. doi:10.1038/mp.2016.29 105. Vinkers CH, Joëls M, Milaneschi Y, et al. Mineralocorticoid receptor haplotypes sex-dependently moderate depression susceptibility following childhood maltreatment. *Psychoneuroendocrinology*. 2015;54:90-102. doi:10.1016/j.psyneuen.2015.01.018 106. Faquih AE, Memon RI, Hafeez H, Zeshan M, Naveed S. A Review of Novel Antidepressants: A Guide for Clinicians. *Cureus*. 2019;11(3). doi:10.7759/cureus.4185 107. de Kloet ER, Otte C, Kumsta R, et al. Stress and Depression: a Crucial Role of the Mineralocorticoid Receptor. *J Neuroendocrinol*. 2016;28(8). doi:10.1111/jne.12379 108. Otte C, Wingenfeld K, Kuehl LK, et al. Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals.*Neuropsychopharmacology*. 2015;40(2):386-393. doi:10.1038/npp.2014.181 109. Vogel S, Klumpers F, Schröder TN, et al. Stress Induces a Shift Towards Striatum-Dependent Stimulus-Response Learning via the Mineralocorticoid Receptor. *Neuropsychopharmacology*. 2017;42(6):1262-1271. doi:10.1038/npp.2016.262 110. Lee CH, Giuliani F. The Role of Inflammation in Depression and Fatigue. *Front Immunol*. 2019;10(July):1696. doi:10.3389/fimmu.2019.01696 111. Kirsch I. Placebo effect in the treatment of depression and anxiety. *Front Psychiatry*. 2019;10(JUN):1-9. doi:10.3389/fpsyt.2019.00407 112. Wang B, Xin N, Qian X, et al. Ahi1 regulates the nuclear translocation of glucocorticoid receptor to modulate stress response.*Transl Psychiatry*. 2021;11(1). doi:10.1038/s41398-021-01305-x 113. Kwon J, Kim YJ, Choi K, Seol S, Kang HJ. Identification of stress resilience module by weighted gene co-expression network analysis in Fkbp5-deficient mice. *Mol Brain*. 2019;12(1):10-13. doi:10.1186/s13041-019-0521-9 114. George SA, Rodriguez-Santiago M, Riley J, Rodriguez E, Liberzon I. The effect of chronic phenytoin administration on single prolonged stress induced extinction retention deficits and glucocorticoid upregulation in the rat medial prefrontal cortex.*Psychopharmacology (Berl)*. 2015;232(1):47-56. doi:10.1007/s00213-014-3635-x 115. Kaczkurkin AN, Foa EB. Cognitive-behavioral therapy for anxiety disorders: An update on the empirical evidence. *Dialogues Clin Neurosci*. 2015;17(3):337-346. doi:10.31887/dcns.2015.17.3/akaczkurkin 116. APA. The Treatment of Depression Across Three Age Cohorts. 2019;(February). https://www.apa.org/depression-guideline/guideline.pdf 117. Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate CA. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. *Int J Neuropsychopharmacol*. 2019;22(2):119-135. doi:10.1093/ijnp/pyy094 118. Kalisch R, Gerlicher AMV, Duvarci S. A Dopaminergic Basis for Fear Extinction. *Trends Cogn Sci*. 2019;23(4):274-277. doi:10.1016/j.tics.2019.01.013 119. Rundo F, Trenta F, di Stallo AL, Battiato S. Machine learning for quantitative finance applications: A survey. *Appl Sci*. 2019;9(24). doi:10.3390/app9245574 120. Europe W. Depression – A review. 2015;(July). 121. Kamal BS, Kamal F, Lantela DE. Cannabis and the Anxiety of Fragmentation—A Systems Approach for Finding an Anxiolytic Cannabis Chemotype. *Front Neurosci*. 2018;12(October). doi:10.3389/fnins.2018.00730 122. Kang DW, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota.*Sci Rep*. 2019;9(1):1-9. doi:10.1038/s41598-019-42183-0 123. Kar SK, Sarkar S. Neuro-stimulation techniques for the management of anxiety disorders: An update. *Clin Psychopharmacol Neurosci*. 2016;14(4):330-337. doi:10.9758/cpn.2016.14.4.330 124. Sharma M. *Comorbidity of Mental and Physical Disorders*. Vol 144.; 2016. doi:10.4103/0971-5916.203466 125. Hyochol Ahn, PhD, Michael Weaver, PhD, Debra Lyon, PhD, Eunyoung Choi, RN, and Roger B. Fillingim P, Tumbar CJFST. 乳鼠心肌提取 HHS Public Access. *Physiol Behav*. 2017;176(1):139-148. doi:10.1016/j.phymed.2016.10.013.Short-term 126. Kim Y-K, Jeon SW. Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders. *Curr Neuropharmacol*. 2018;16(5):574-582. doi:10.2174/1570159x15666170913110426 127. King G, Baker KD, Bisby MA, et al. A precision medicine approach to pharmacological adjuncts to extinction: a call to broaden research.*Psychopharmacology (Berl)*. 2019;236(1):143-161. doi:10.1007/s00213-018-4999-0 128.

Knight LK, Depue BE. New frontiers in anxiety research: The translational potential of the bed nucleus of the stria terminalis.*Front Psychiatry*. 2019;10(JULY):1-7. doi:10.3389/fpsyt.2019.00510 129. Kodal A, Fjermestad K, Bjelland I, et al. Long-term effectiveness of cognitive behavioral therapy for youth with anxiety disorders.*J Anxiety Disord*. 2018;53(August 2017):58-67. doi:10.1016/j.janxdis.2017.11.003 130. Rebello TJ, Keeley JW, Kogan CS, et al. Anxiety and Fear-Related Disorders in the ICD-11: Results from a Global Case-controlled Field Study. *Arch Med Res*. 2019;50(8):490-501. doi:10.1016/j.arcmed.2019.12.012 131. Kolar D. Addictive potential of novel treatments for refractory depression and anxiety. *Neuropsychiatr Dis Treat*. 2018;14:1513-1519. doi:10.2147/NDT.S167538 132. Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. *Biol Psychiatry*. 2015;78(8):572-581. doi:10.1016/j.biopsych.2014.04.010 133. Krystal JH, Davis LL, Neylan TC, et al. It Is Time to Address the Crisis in the Pharmacotherapy of Posttraumatic Stress Disorder: A Consensus Statement of the PTSD Psychopharmacology Working Group.*Biol Psychiatry*. 2017;82(7):e51-e59. doi:10.1016/j.biopsych.2017.03.007 134. Kyrou I, Christou A, Panagiotakos D, et al. Effects of a hops (Humulus lupulus l.) dry extract supplement on self-reported depression, anxiety and stress levels in apparently healthy young adults: A randomized, placebo-controlled, double-blind, crossover pilot study.*Hormones*. 2017;16(2):171-180. doi:10.14310/horm.2002.1738 135. Nielsen ND, Sandager M, Stafford GI, Van Staden J, Jäger AK. Screening of indigenous plants from South Africa for affinity to the serotonin reuptake transport protein. *J Ethnopharmacol*. 2004;94(1):159-163. doi:10.1016/j.jep.2004.05.013 136. Zhou D, Jin H, Lin HB, et al. Antidepressant effect of the extracts from Fructus Akebiae. *Pharmacol Biochem Behav*. 2010;94(3):488-495. doi:10.1016/j.pbb.2009.11.003 137. Sakakibara H, Yoshino S, Kawai Y, Terao J. Antidepressant-like effect of onion (Allium cepa L.) powder in a rat behavioral model of depression. *Biosci Biotechnol Biochem*. 2008;72(1):94-100. doi:10.1271/bbb.70454 138. Ding H, Wang H, Zhu L, Wei W. Ursolic Acid Ameliorates Early Brain Injury After Experimental Traumatic Brain Injury in Mice by Activating the Nrf2 Pathway. *Neurochem Res*. 2017;42(2):337-346. doi:10.1007/s11064-016-2077-8 139. Wang YJ, Lu J, Wu D mei, et al. Ursolic acid attenuates lipopolysaccharide-induced cognitive deficits in mouse brain through suppressing p38/NF-κB mediated inflammatory pathways. *Neurobiol Learn Mem*. 2011;96(2):156-165. doi:10.1016/j.nlm.2011.03.010 140. Mourya A, Akhtar A, Ahuja S, Sah SP, Kumar A. Synergistic action of ursolic acid and metformin in experimental model of insulin resistance and related behavioral alterations. *Eur J Pharmacol*. 2018;835(July):31-40. doi:10.1016/j.ejphar.2018.07.056